Quarterly ResultMay 14, 2026, 07:27 AM
GH Research Q1 Loss $19.0M; Cash $267.3M; Phase 3 Prep
AI Summary
GH Research PLC reported a net loss of $19.0 million, or $0.31 per share, for the first quarter of 2026, an increase from $10.8 million loss in Q1 2025, driven by higher R&D and G&A expenses. The company ended the quarter with $267.3 million in cash, cash equivalents, and marketable securities, further bolstered by $111.2 million in net proceeds from an underwritten offering in April 2026. Key business updates include the publication of Phase 2b TRD trial results, completion of studies for the global Phase 3 pivotal program of GH001, and completion of a US IND-opening study.
Key Highlights
- Q1 2026 net loss was $19.0 million, up from $10.8 million in Q1 2025.
- Basic and diluted loss per share was $0.31 for Q1 2026, compared to $0.19 in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $267.3 million as of March 31, 2026.
- Received $111.2 million in net cash proceeds from an underwritten offering in April 2026.
- Research and development expenses increased to $12.4 million from $7.9 million year-over-year.
- General and administration expenses rose to $6.4 million from $4.9 million year-over-year.
- Phase 2b TRD trial results published in JAMA Psychiatry.
- Completed studies for global Phase 3 pivotal program of GH001 in TRD.